| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.071 | 0.02 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | selumetinib:tretinoin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |